Trial · NCT07910201
The Impact of Osteosarcopenia on Falls, Kinesiophobia, and Quality of Life in Postmenopausal Women
NCT07910201, Active not recruiting, Ayşe Ukbe Baykut
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Impact of Osteosarcopenia on Falls, Kinesiophobia, and Quality of Life in Postmenopausal Women. Trials, record NCT07910201. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910201
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Impact of Osteosarcopenia on Falls, Kinesiophobia, and Quality of Life in Postmenopausal Women
- NCT number
- NCT07910201
- Status
- Active not recruiting
- Enrollment
- 109 participants, actual
- Lead sponsor
- Ayşe Ukbe Baykut
- Conditions
- Osteosarcopenia, Sarcopenia, Postmenopausal Osteoporosis, Kinesiophobia, Fear of Falling
- Interventions
- Dual-energy x-ray absorptiometer
- First posted
- 2026-11-02
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tampa Scale for Kinesiophobia | baseline | The Tampa Scale for Kinesiophobia will be used to assess the fear of movement in patients. The scale consists of 17 items, with each item scored on a scale from 1 to 4. The minimum score that can be obtained is 17, and the maximum score is 68. In the studies, a score of 37 or higher has been defined as kinesiophobia. |
| Primary | International Falls Efficacy Scale | baseline | The level of concern regarding falling will be assessed using the International Falls Efficacy Scale . The scale consists of 16 items, with each item scored on a scale from 1 to 4. The minimum possible score is 16 and the maximum is 64; a score of ≤19 indicates a low fear of falling, while a score of ≥28 indicates a high fear of falling. |
| Primary | Short Form-36 Health Survey (SF-36) | baseline | The Short Form-36 Health Survey will be used to assess quality of life. It is a scale consisting of 8 subdimensions and a total of 36 items. The scoring ranges from 0 to 100, with higher scores indicating a better quality of life. |
| Secondary | Grip strength | baseline | A Baseline hydraulic hand dynamometer (INC., White Plains, NY 10602, U.S.A.) will be used to measure grip strength. Grip strength will be assessed three times for each hand while the individual is seated in a chair, and the highest value obtained will be recorded. |
| Secondary | Fracture Risk Assessment Tool | baseline | The Fracture Risk Assessment Tool will be used to estimate the 10-year probability of fractures, specifically calculating the risk for major osteoporotic fractures and hip fractures. |
| Secondary | calf circumference | baseline | For the calf circumference measurement, the measurement should be taken at the widest part of the calf while standing. |
| Secondary | gait speed test | baseline | For the gait speed test, patients will be asked to walk at a normal pace along a flat surface over a distance of 4 meters-from a designated starting point to an end point-while the time taken is measured using a stopwatch; the gait speed will then be calculated. |
| Secondary | Chair sit-to-stand test | baseline | In the sit-to-stand test, the time required for patients to stand up and sit down five times while seated on a chair without armrests will be recorded. This will be performed twice, and the fastest time measured will be recorded. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910201
GET https://conductscience.org/api/trials/v1/NCT07910201/registered